In this webinar, you will learn:
- How mAb irreproducibility could unknowingly impact your research outcomes
- Proven strategies to mitigate reproducibility risks when using research reagents
- The role of antibody sequencing in ensuring reproducibility with mAbs
- Rapid, cost-effective sequence confirmation for routine applications
- The next frontier: polyclonal antibody sequencing and recombinant pAbs
Researchers often purchase antibodies expecting reliability, only to face failed experiments, irreproducible results, and wasted time and money. Nearly 50% of commercial antibodies fail to meet basic characterization standards, resulting in an estimated $0.4–1.8 billion in annual losses in the U.S.
Monoclonal antibodies (mAbs) produced in hybridomas and polyclonal antibodies (pAbs) produced from immunized animal serum have significant drawbacks. We have seen it all – additional productive chains, oligoclonal-like mAbs, batch-to-batch variability, all of which contribute to misleading results and irreproducible research.
To combat this, using sequence-defined recombinantly produced antibodies ensures consistency in binding and behavior due to their characterized sequences.
We will present case studies demonstrating how techniques like mAb sequencing, antibody sequence confirmation, and pAb conversion can enhance research reliability.
Speaker Bios
Iain Rogers, MBA
Rapid Novor
VP Commercial
Iain began working in mass spectrometry and proteomics in 2004. Since then, he has founded and exited two startups and earned an MBA from Cornell University and Queen’s University. Iain joined Rapid Novor in 2021, to lead the commercialization of our technology.
Genya Gorshtein, MSc
Rapid Novor
Scientific Liaison
Genya holds a Master’s degree in Molecular and Cellular Biology from the University of Guelph, where she honed her skills in translating complex scientific concepts into accessible knowledge. At Rapid Novor, she creates educational content and curates case studies on de novo antibody sequencing applications.